Bone Marrow-Derived Mesenchymal Stem Cells Ameliorate Autoimmune Enteropathy Independently of Regulatory T Cells
- 17 April 2008
- journal article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 26 (7), 1913-1919
- https://doi.org/10.1634/stemcells.2007-0790
Abstract
Cell-based tolerogenic therapy is a relatively new approach for the treatment of autoimmune diseases. Mesenchymal stem cells (MSCs) have been shown to be potent immunomodulatory agents in a number of experimental and clinical scenarios; however, their use in various autoimmune diseases is undefined. Herein, we report the efficacy of MSC transplantation in a multiorgan autoimmunity model. Mice with defective peripheral tolerance caused by a deficiency in regulatory T cells were used as a testbed for therapy. After screening multiple target tissues of autoimmune attack, we observed an MSC-specific improvement in the histopathology of the distal ileum of treated mice. We then showed that MSCs can reduce mesenteric lymph node (MLN) cellularity in autoimmune mice during active disease and decrease activated T-cell populations in the MLN. Trafficking studies using enhanced green fluorescent protein (eGFP)-reporter MSCs revealed no appreciable engraftment in the intestine, but it did reveal the presence of eGFP+ cells organized in clusters within the MLN, as well as ancillary nodes. Semiquantitative analysis showed no difference in the number of clusters; however, eGFP+ cells in MLNs compared with ancillary nodes had distinct fibroblastoid morphology and formed a network with neighboring eGFP+ cells. Finally, we show evidence that transplantation of MSCs caused global immunosuppression, as measured by increased CD4+ CD8+ thymocyte production and serum interleukin-10 and decreased serum interferon-γ. These data implicate the intestine as a new site of MSC tolerance induction and should motivate additional studies evaluating the use of MSCs as a treatment for autoimmune enteropathies. Disclosure of potential conflicts of interest is found at the end of this article.Keywords
This publication has 41 references indexed in Scilit:
- Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic FailurePLOS ONE, 2007
- Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen‐induced arthritisArthritis & Rheumatism, 2007
- Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like diseaseThe Journal of Experimental Medicine, 2007
- Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/ scid miceProceedings of the National Academy of Sciences of the United States of America, 2006
- Earlier Onset of Syngeneic Tumors in the Presence of Mesenchymal Stem CellsTransplantation, 2006
- Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative responseThe Esophagus, 2005
- Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergyPublished by American Society of Hematology ,2005
- Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathwayEuropean Journal of Immunology, 2005
- Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2004
- Gut instincts: thoughts on intestinal epithelial stem cellsJCI Insight, 2000